TMCnet News
Erasca to Present at the Guggenheim Oncology Conference 2023SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Oncology Conference 2023. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a fireside chat beginning at 1:00 pm Eastern Time on Wednesday, February 8, 2023. Drs. Lim and Chacko will also participate in one-on-one investor meetings. A live webcast of the event will be available Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events. About Erasca Contact: Source: Erasca, Inc. |